For the year ending 2025-12-31, PLSE had -$37,303K decrease in cash & cash equivalents over the period. -$54,437K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -72,781 |
| Depreciation | 406 |
| Amortization of intangible assets | 665 |
| Stock-based compensation | 21,457 |
| Non-cash lease expense | 1,153 |
| Loss on disposal of fixed assets | 0 |
| Accounts receivable | 274 |
| Inventory | 136 |
| Prepaid expenses and other current assets | 912 |
| Other non-current assets | 14 |
| Accounts payable | 1,132 |
| Accrued liabilities | -3,450 |
| Lease liabilities, net | -1,368 |
| Net cash used in operating activities | -54,122 |
| Purchases of property and equipment | 315 |
| Purchases of intangible assets | 20 |
| Net cash used in investing activities | -335 |
| Proceeds from issuance of common stock under employee stock purchase plan | 586 |
| Proceeds from exercises of warrants, net of issuance costs | 14,081 |
| Proceeds from exercises of stock options | 2,487 |
| Proceeds from issuance of common stock and warrants in relation to rights offering, net of issuance costs | 0 |
| Payment of deferred issuance costs in relation to at-the-market equity offering program | 0 |
| Net cash provided by financing activities | 17,154 |
| Net (decrease) increase in cash and cash equivalents | -37,303 |
PULSE BIOSCIENCES, INC. (PLSE)
PULSE BIOSCIENCES, INC. (PLSE)